Relapsed/Refractory Diffuse Large B-Cell Lymphoma Study
Phase: 2/3
Status: Ongoing
About
A Phase 2/3 Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Details
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
Sponsor: Karyopharm Therapeutics Inc
NCT04442022
